Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is used in the treatment of metastatic colorectal cancer and other solid tumors in adult patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Accord is a topoisomerase I inhibitor used in oncology to target malignant cells. - Metastatic colorectal cancer: used in combination regimens to inhibit tumor growth and improve survival. - Advanced colorectal cancer: employed as part of first‑line or later‑line therapy to control disease progression. - Other solid tumors: provided in selected cases where topoisomerase I inhibition offers antineoplastic benefit.

Irinotecan Accord may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: managed with antiemetics. - Neutropenia: monitor blood counts regularly. - Fatigue: may affect daily activities. - Alopecia: hair loss can occur during treatment. - Abdominal pain: may accompany gastrointestinal upset.

Serious or Rare Side Effects: - Febrile neutropenia: risk of infection requiring prompt medical attention. - Severe diarrhea (colitis): can lead to dehydration and electrolyte imbalance. - Cholinergic syndrome: characterized by sweating, salivation, and bronchospasm. - Hypersensitivity reactions: including rash, fever, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes indicating liver injury.

Prior to initiating Irinotecan Accord, several safety considerations are recommended. - Dose adjustment in hepatic impairment: reduce dose according to liver function tests. - Monitor blood counts: perform regular CBC to detect neutropenia early. - Assess for diarrhea: initiate antidiarrheal measures at first sign. - Avoid in pregnancy: contraindicated due to fetal risk (Category D). - Store at controlled room temperature: keep in original container, protect from light and moisture.

Irinotecan may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may lower irinotecan exposure and efficacy. - Concurrent use of other topoisomerase I inhibitors: increases risk of overlapping toxicity. - Live vaccines: immunosuppression can lead to infection.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk. - UGT1A1 inhibitors: can raise SN‑38 levels and toxicity. - Drugs causing electrolyte imbalance: may worsen irinotecan‑related diarrhea.